A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF COMBINED ORAL C-MET/ALK INHIBITOR (PF-02341066) AND PAN-HER INHIBITOR (PF-00299804) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER

Objective

Clinical trial of PF-00299804 or that will be administered by mouth and is investigational combined with PF-00299804 that will be administered by mouth and is investigational.

IRB Protocol Number

10-0552

Principal Investigator(s)

ROSS CAMIDGE

Cancer Trials

• Lung Cancer

Sponsor(s)

Pfizer

Contact

AMY BROWN at 720-848-0603
or AMY.M.BROWN@UCDENVER.EDU

Eligibility and Other Participant Information

What To Expect : A screening period to determine eligibility. A treatment period (s) that can last as long as your disease doesn't progress or until the end of the study. A follow up period will consist of contact by phone or clinic visit 28 days after treatment ended. // Eligibility criteria include but are not limited to 18 years or older with non-small cell lung cancer.